Somite Therapeutics, a Boston-based TechBio company, raised a $4.8M extension to its pre-seed funding.

The round, led by Astellas Venture Management and Montage Ventures, included contributions from notable figures such as Nachum Shamir and Paul and Dr. Kendra Harris.

Funds will expedite data generation for the AI platform AlphaStem, advance SMT-M01 for Duchenne muscular dystrophy, initiate SMT-B01 for metabolic disorders, and research hypoimmune cell lines.

Led by CEO Dr. Micha Breakstone, Somite Therapeutics leverages AI to develop scalable cell therapies for various diseases.